CHCWM – Cancer & Hematology Centers of West Michigan

SGN B7H4V-001 (Seagen, Inc.)

Description:  A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

Mechanism of Action:  .antibody drug conjugate to B7H4V.  B7H4 is an immune checkpoint protein present on cancer cells

Target Patient Population:  Ovarian, Primary peritoneal or Fallopian, Breast (HER2-, HR+), Triple Negative Breast, Endometrial, Squamous Non Small Cell Lung, Cholangiocarcinoma, Gallbladder cancers.

Study Design:  Drug is administered IV 21 day cycle (Day 1, 8 or Day 1 only)